SIRPA and neoplasm: To block CD47 on tumor cells, an exosome was genetically engineered to express a high-affinity variant of SIRPα for CD47 surface binding at a minimal quantity, initiating phagocytic clearance of cancer cells (Fig. 2d) [43].